Cartesian Therapeutics, Inc. · NASDAQ:RNAC

Cartesian Therapeutics — Selecta Biosciences — Investor Presentation (February 2022)

40 slides from Cartesian Therapeutics's investor presentation, Feb 16, 2022

  1. Slide 1: Selecta Biosciences Corporate Presentation

    February 2022 Selecta Biosciences Corporate Presentation SELB

  2. Slide 2: 2Selecta Any statements in this presentation about the future expectations, plans and prospects of

    2Selecta Biosciences Corporate Presentation – Feb. 2022 Any statements in this presentation about the future expectations, plans and prospects of Selecta Biosciences, Inc. (“the company”), including without limitation, statements regarding the progress of the clinical development of SEL-212, the pot

  3. Slide 3: Pioneering Precision Immune Tolerance

    3Selecta Biosciences Corporate Presentation – Feb. 2022 PLACEHOLDER FOR SPLASH PAGE @Jess can you pull in design elements from the website for this page? Pioneering Precision Immune Tolerance

  4. Slide 4: Investment Highlights

    4Selecta Biosciences Corporate Presentation – Feb. 2022 Investment Highlights ImmTOR™ platform has potentially broad applicability • Precision immune tolerance platform has potential to restore self tolerance in autoimmune disease and overcome immunogenicity of gene therapies and biologics • Preclin

  5. Slide 5: ImmTOR Platform Precision Immune Tolerance

    5 ImmTOR Platform Precision Immune Tolerance

  6. Slide 6: ImmTOR is a precision immune tolerance platform with broad applicability

    6Selecta Biosciences Corporate Presentation – Feb. 2022 ImmTOR is a precision immune tolerance platform with broad applicability ImmTOR combines nanoparticle technology with an FDA approved anti-inflammatory and immunomodulatory drug, and is designed to generate antigen-specific immune tolerance whe

  7. Slide 7: ImmTOR could restore self tolerance in autoimmune disease and overcome immunogenicity

    7Selecta Biosciences Corporate Presentation – Feb. 2022 ImmTOR could potentially be applied to restore self tolerance in autoimmune disease and overcome immunogenicity of gene therapies and biologics Autoimmune Disease Gene Therapies/Biologics

  8. Slide 8: ImmTOR-IL: ImmTOR plus IL-2 agonist

    8Selecta Biosciences Corporate Presentation – Feb. 2022 ImmTOR-IL : ImmTOR plus IL-2 agonist ImmTOR-IL IL-2 agonist Synergistic activity of ImmTOR and a Treg-selective IL-2:  Observed to increase the magnitude and durability of antigen-specific Treg expansion when compared to either ImmTOR or IL-2

  9. Slide 9: Aiming to restore self tolerance to auto antigens and power biologics

    9Selecta Biosciences Corporate Presentation – Feb. 2022 Aiming to restore self tolerance to auto antigens and power biologics Biologic Therapies Gene Therapies Tolerogenic Therapies ImmTOR is designed to address the immunogenicity of biologics ImmTOR potentially enables redosing of transformative ge

  10. Slide 10: A diversified and growing wholly-owned pipeline

    10Selecta Biosciences Corporate Presentation – Feb. 2022 c A diversified and growing wholly-owned pipeline Recent and Upcoming Milestones TOLEROGENIC THERAPIES Indication Antigen Preclinical Phase 1 Phase 3Phase 2 Commercial Rights BIOLOGIC THERAPIES Ornithine Transcarbamylase (OTC) Deficiency AAV-h

  11. Slide 11: Strategic collaborations and license agreements

    11Selecta Biosciences Corporate Presentation – Feb. 2022 Collaboration Year 2019 2020 2020 2021 2021 2021 2021 2022 ImmTOR Approach Gene Therapy Biologic Gene Therapy Autoimmune Gene Therapy Gene Therapy Biologic Gene Therapy Agreement Strategic Collaboration and License Agreement License Agreement

  12. Slide 12: Restoring Self-Tolerance in Autoimmune Disease

    12 Restoring Self-Tolerance in Autoimmune Disease

  13. Slide 13: Striving to restore self-tolerance in autoimmune diseases

    13Selecta Biosciences Corporate Presentation – Feb. 2022 Striving to restore self-tolerance in autoimmune diseases ImmTOR + IL-2 has the potential to be a best-in-class approach There are roughly 80 autoimmune conditions that affect as much as 4.5% of the world’s population*. 24M+ individuals in the

  14. Slide 14: Expanding the platform by amplifying the effect of ImmTOR with IL-2

    14Selecta Biosciences Corporate Presentation – Feb. 2022 Expanding the platform by amplifying the effect of ImmTOR with IL-2  Synergistic activity in increasing the percentage and durability of Treg expansion in the spleen  Opportunity to restore tolerance in a wide range of autoimmune diseases 

  15. Slide 15: Induction and expansion of antigen-specific Treg

    15Selecta Biosciences Corporate Presentation – Feb. 2022 Induction and expansion of antigen-specific Treg Observed a significant expansion of antigen-specific Treg* with a single dose of ImmTOR in combination with an IL-2 mutein + antigen C D 4+ C D 25 + F o x P 3+ ( % , o f C D 4 + C D 45 .2 + ) 0

  16. Slide 16: Superior anti-AAV antibody inhibition when IL-2 is combined with ImmTOR

    16Selecta Biosciences Corporate Presentation – Feb. 2022 Superior anti-AAV antibody inhibition observed when IL-2 is combined with ImmTOR Clear dose sparing effect seen when IL-2 mutein is combined with ImmTOR* A n ti- A A V I g G ( O D 4 5 0 -5 7 0 ) 12 19 33 47 61 75 91 104 117 0.0 0.5 1.0 1.5 2.0

  17. Slide 17: ImmTOR-based approach to treating primary biliary cholangitis

    17Selecta Biosciences Corporate Presentation – Feb. 2022 Hepatic regulatory T cells Tolerogenic liver sinusoidal endothelial cells We believe ImmTOR is ideally suited to address PBC PBC is a T-cell mediated disease driven by a well-defined antigen, ImmTOR biodistributes to the liver and induces a to

  18. Slide 18: Gene Therapy

    18 Gene Therapy

  19. Slide 19: AAV gene therapies are coming of age but still have challenges

    19Selecta Biosciences Corporate Presentation – Feb. 2022 AAV gene therapies are coming of age but still have challenges Selecta has platform technologies to potentially address many key challenges facing the modality ImmTOR – Human proof of concept shows the ability of ImmTOR to inhibit the formatio

  20. Slide 20: Potential for ImmTOR to enhance AAV gene therapies

    20Selecta Biosciences Corporate Presentation – Feb. 2022 Potential for ImmTOR to enhance AAV gene therapies Safer, more durable AAV gene therapy treatments are within reach

  21. Slide 21: Aiming to address two key challenges in AAV gene therapy

    21Selecta Biosciences Corporate Presentation – Feb. 2022 Aiming to simultaneously address two key challenges in AAV gene therapy + = ImmTOR Xork • Potential to increase the number of patients eligible for gene therapy by mitigating pre-existing anti-AAV antibodies • Potential to enable re-dosing by

  22. Slide 22: ImmTOR enhances transgene expression after first and second AAV doses

    22Selecta Biosciences Corporate Presentation – Feb. 2022 Time after initial AAV treatment (d) ImmTOR has been shown to enhance transgene expression after first and second doses of AAV Repeat dosing enabled by ImmTOR is dose sparing 5e11 vg/kg AAV-SEAP 5e11 vg/kg AAAV-SEAP + ImmTOR 25e11 vg/kg AAV-SE

  23. Slide 23: Single dose ImmTOR inhibited formation of anti-AAV8 NAb at day 30

    23Selecta Biosciences Corporate Presentation – Feb. 2022 Single dose ImmTOR inhibited formation of anti-AAV8 NAb at day 30 100% of subjects dosed with 0.3 mg/kg ImmTOR had NAb titers ≤1:25 at Day 30 67% of subjects dosed with 0.3 mg/kg ImmTOR had NAb titers ≤1:5 at Day 30 2000 1000 100 10Lo g 1 0 N

  24. Slide 24: Single dose ImmTOR inhibited median anti-AAV8 NAb dose-dependently

    24Selecta Biosciences Corporate Presentation – Feb. 2022 Single dose ImmTOR inhibited formation of median anti-AAV8 NAb in a dose- dependent manner at day 30 1:5 Median NAb titers in subjects dosed with 0.3 mg/kg ImmTOR at Day 30 250-fold lower median NAb titers in subjects dosed with 0.3 mg/kg ImmT

  25. Slide 25: Delayed NAb formation by day 90

    25Selecta Biosciences Corporate Presentation – Feb. 2022 Subjects treated with a single dose of ImmTOR developed delayed NAb formation by day 90 2 of 6 subjects dosed with 0.3 mg/kg ImmTOR had NAb titers ≤1:25 at Day 90 1 of 6 subjects dosed with 0.3 mg/kg ImmTOR had NAb titers ≤1:5 at Day 90 Titer

  26. Slide 26: Empty capsid data in-line with NHP data at day 90

    26Selecta Biosciences Corporate Presentation – Feb. 2022 Empty capsid data in-line with single dose ImmTOR NHP data at day 90 Antibody levels may interfere with efficient re-dosing** Titers too high for re-dosing Patients eligible for re-dosing* (Zolgensma eligibility: ≤1:50) * May be dependent on g

  27. Slide 27: Summary and conclusions

    27Selecta Biosciences Corporate Presentation – Feb. 2022 Summary and conclusions  AAV8 empty capsids elicited a strong immune response with peak median anti-AAV8 NAb titers of 1:6875  ImmTOR inhibited the formation of anti-AAV8 NAb in a dose-dependent manner at Day 30  After Day 30, 2 of 6 subjec

  28. Slide 28: SEL-302 - Gene therapy program for the treatment of MMA

    28Selecta Biosciences Corporate Presentation – Feb. 2022 SEL-302 - Gene therapy program for the treatment of MMA IND filed in Q3 2021 • Methylmalonic acidemia (MMA) is a rare monogenic metabolic disease with a potential live birth incidence of between 1:25,000 and 1:48,000 1 • Majority of patients h

  29. Slide 29: Biologics

    29 Biologics

  30. Slide 30: Challenges of immunogenic biologics

    30Selecta Biosciences Corporate Presentation – Feb. 2022 cTHE Challenges Many biologics can be highly immunogenic resulting in suboptimal responses to the standard of care due to the development of anti-drug antibodies (ADAs) after multiple treatments Patients that develop an immune response to the

  31. Slide 31: Pegadricase is highly immunogenic when given alone

    31Selecta Biosciences Corporate Presentation – Feb. 2022 Pegadricase is highly immunogenic when given alone Pegadricase is a highly immunogenic enzyme with most patients treated with pegadricase alone developing anti-drug antibodies within 2 weeks after a single treatment Days after treatment 0 5 10

  32. Slide 32: SEL-212 tophi responder analysis versus pegloticase

    32Selecta Biosciences Corporate Presentation – Feb. 2022 1. Number of patients with tophi with Responder Assessment 2. Treatment difference = SEL-212 percent responder - pegloticase percent responder. Rounded to nearest integer Evaluation Period (Month) Data Set SEL-212 pegloticase Treatment Differe

  33. Slide 33: SEL-212 phase 3 DISSOLVE program design

    33Selecta Biosciences Corporate Presentation – Feb. 2022 SEL-212 phase 3 DISSOLVE program design Evaluating SEL-212 in a pivotal phase 3 program versus placebo, with topline data expected in Q4 2022 • 2 double blinded placebo-controlled trials of SEL-212 (0.1 mg/kg & 0.15 mg/kg ImmTOR) − Both studie

  34. Slide 34: Opportunity to address unmet medical needs for the treatment of IgAN

    34Selecta Biosciences Corporate Presentation – Feb. 2022 Opportunity to address unmet medical needs for the treatment of IgAN • Immunoglobulin A nephropathy (IgAN) is a leading cause of chronic kidney disease (CKD) and renal failure with 30-40% of patients reaching end-stage renal disease; approxima

  35. Slide 35: Combining ImmTOR with IgA protease for the treatment of IgAN

    35Selecta Biosciences Corporate Presentation – Feb. 2022 Combining ImmTOR with IgA protease for the treatment of IgAN Building on the clinical data from the SEL-212 program and strong preclinical data in IgA Saline IgA protease 5mg/kg IV Glomerular IgA1 deposits Complement deposition Fibronectin Ada

  36. Slide 36: Corporate

    36 Corporate

  37. Slide 37: Experienced management team positions Selecta for success

    37Selecta Biosciences Corporate Presentation – Feb. 2022 Peter G. Traber, M.D. Chief Medical Officer Experienced management team positions Selecta for success Lloyd Johnston, Ph.D. Chief Operations Officer Carsten Brunn, Ph.D. President and CEO Kei Kishimoto, Ph.D. Chief Scientific Officer Kristen B

  38. Slide 38: Financial information at-a-glance

    38Selecta Biosciences Corporate Presentation – Feb. 2022 (1) Includes cash, cash equivalents, marketable securities and restricted cash. • Phase 1 clinical trial initiation and preliminary SEL-302 data in MMA • Enzyme candidate selection and IND enabling studies in IgA Nephropathy • Develop a propri

  39. Slide 39: Investment Highlights

    39Selecta Biosciences Corporate Presentation – Feb. 2022 Investment Highlights ImmTOR™ platform has potentially broad applicability • Precision immune tolerance platform has potential to restore self tolerance in autoimmune disease and overcome immunogenicity of gene therapies and biologics • Precli

  40. Slide 40: Contact: Selecta Biosciences, Inc.

    40 Contact: SELECTA BIOSCIENCES, INC. 65 Grove Street Watertown, MA 02472 617-923-1400 info@selectabio.com

Selecta Biosciences — Investor Presentation (February 2022) on 6ix